Oral vs Intravenous Dexamethasone in Total Knee Arthroplasty
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 80 years old?
Source: NCT07442812, who can take part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Haseki Training and Research Hospital
- Trial code
- NCT07442812
- Record updated
- 1 September 2026
- Original description
This prospective observational cohort study aims to evaluate the association between perioperative dexamethasone administration and early postoperative recovery following primary total knee arthroplasty. In routine clinical practice, dexamethasone may be administered orally, intravenously, or not administered, depending on the surgeon's established perioperative protocol.Read full original descriptionShow less
The Role of Dexamethasone in Total Knee Arthroplasty: Effects of Oral and Intravenous Administration on Early Postoperative Pain and Mobilization
This prospective observational cohort study aims to evaluate the association between perioperative dexamethasone administration and early postoperative recovery following primary total knee arthroplasty. In routine clinical practice, dexamethasone may be administered orally, intravenously, or not administered, depending on the surgeon's established perioperative protocol.
The primary objective is to assess early postoperative recovery in terms of pain intensity, functional mobility, and knee joint range of motion. Secondary objectives include evaluation of inflammatory response, postoperative metabolic changes, opioid requirement, and the severity of postoperative nausea and vomiting (PONV).
Group allocation is non-randomized and determined solely by the standard perioperative management approach routinely applied by the surgeon selected by the patient. No additional interventions are introduced for research purposes. All outcomes are assessed prospectively during the early postoperative period.
Inclusion: Age between 50 and 80 years; Diagnosis of primary knee osteoarthritis (primary gonarthrosis); Scheduled for elective primary total knee arthroplasty; ASA physical status I or II; Ability to ambulate independently (with or without assistive devices) preoperatively; Ability to understand study procedures and complete pain and functional assessments; Provision of written informed consent.
Exclusion: Chronic systemic corticosteroid use; History of knee joint infection; Uncontrolled diabetes mellitus; Active infection at any site; Known hypersensitivity to corticosteroids; Severe hepatic, renal, or cardiac disease; Neurological or musculoskeletal disorders affecting gait or balance; Known endocrine disorders affecting glucose metabolism; Revision total knee arthroplasty; Inflammatory arthritis (e.g., rheumatoid arthritis); Inability or unwillingness to comply with study procedures.